StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Zerbaxa (ceftolozane and tazobactam) by Quarter

Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

QuarterlyAnnual

Merck Zerbaxa (ceftolozane and tazobactam): 2.0% in Q2 2026, down 19.0 pts from a year earlier.

Latest, Q2 2026
2.0%
Period ended Jun 30, 2026
Change on a year earlier
-19.0 pts
21.0% in Q2 2025
History
19 quarters
Since Q1 2020
Sources
19
Documents cited below

Where the Q2 2026 figure comes from

“|| Zerbaxa | 82 | 77 | 159 | 70 | 74 | 145 | 81 | 87 | 312 | 4 | 2 | 10 | 8”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20262.0%-19.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202523.0%+7.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202524.0%–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202521.0%+3.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q4 2024Dec 31, 202416.0%-7.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 202418.0%0.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202415.0%-55.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202323.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202322.0%–Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202318.0%–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 202370.0%–Form 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q4 2021Dec 31, 2021-47.0%-5.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-105.0%-129.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2021Jun 30, 2021-104.0%-127.0 ptsForm 8-K (tm2123400d1_ex99-1.htm, filed 2021-07-29) ↗
Q1 2021Mar 31, 2021-120.0%-162.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 2020-42.0%–Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Cite this data

StockData. (2026). Merck Zerbaxa (ceftolozane and tazobactam) (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zerbaxa-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.